Skip to content

NIV for Hypercapnic Respiratory Failure: AVAPS vs S/T BIPAP

NIV for Hypercapnic Respiratory Failure: AVAPS vs S/T BIPAP

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06047405
Enrollment
100
Registered
2023-09-21
Start date
2023-10-07
Completion date
2026-09-01
Last updated
2023-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercapnic Respiratory Failure

Keywords

AVAPS, BIPAP, Hypercapnic respiratory failure, Noninvasive ventilation

Brief summary

The goal of this study is to compare two different modes of noninvasive ventilation in hypercapnic respiratory failure. The investigators will compare AVAPS and BIPAP S/T and hypothesize that AVAPS will result in a decreased length of stay in the ICU or on telemetry. Currently, noninvasive ventilation is the standard of care for hypercapnic respiratory failure. However, the most effective mode for patients with hypercapnic respiratory failure is unclear.

Detailed description

1\. Overall Study Design and Plan This is a single center, randomized trial that will include a total of 100 adult subjects aged 18 or older with hypercapnic respiratory failure of all etiologies (i.e. all comers). The investigators will randomize patients in a single-blinded (patient blinded) fashion to BIPAP S/T or AVAPS during the duration of their hospitalization. The investigators will assess ABG at baseline, 1 hour after initial placement on BIPAP S/T or AVAPS, and between hours 24-48 of use. The investigators will record the pre-NIV pH and PaCO2, post-NIV pH and PaCO2, length of hospital stay in the medical ICU or telemetry unit, days on NIV, need for intubation (if occurred), transition to medical ICU care in patients who were initially admitted to telemetry, and in-hospital mortality. All collected laboratory data are already done as part of usual care for all patients placed on NIV when a patient is on the telemetry unit or medical ICU. The groups will undergo stratified randomization based on whether they are initially admitted to medical ICU or medical telemetry. Patients from medical ICU or telemetry units will be randomized to one of the following arms: Arm 1: AVAPS mode Arm 2 2: BIPAP S/T mode

Interventions

DEVICEAverage Volume-Assured Pressure Support (AVAPS)

A setting on noninvasive ventilator that allows setting of maximum and minimum inspiratory pressure and sets a target tidal volume. The inspiratory pressure varies breath to breath to ensure pre-set tidal volume is delivered.

DEVICEBilevel Positive Airway Pressure Spontaneous Timed (BIPAP S/T)

A setting on noninvasive ventilator that allows setting of inspiratory pressure, inspiratory time, expiratory pressure, and backup rate to deliver variable tidal volumes.

Sponsors

Northwell Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Patients from medical ICU or telemetry units will be randomized to one of the following arms: Arm 1: AVAPS mode Arm 2: BIPAP S/T mode

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Provision of signed and dated informed consent form directly by the patient; consent can also be obtained via a legal patient representative/health care proxy/surrogate 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged 18 or older 4. Diagnosed with hypercapnic respiratory failure on admission (ABG) 5. Admitted to Lenox Hill Hospital medical intensive care unit or telemetry unit 6. Requiring noninvasive ventilation as determined by the treating physician for the treatment of hypercarbic respiratory failure

Exclusion criteria

1. Patients who require ventilation at predetermined tidal volumes 2. Patients who require rapid and frequent IPAP adjustments to maintain a consistent tidal volume 3. Age less than 18 years of age 4. Currently intubated 5. Chronic tracheostomy 6. Pregnancy 7. Hypotension 8. Epistaxis (nosebleed) 9. Untreated pertussis 10. Acute sinusitis or Otitis media 11. Patients at risk of aspirating gastric contents 12. Patients with lack of spontaneous respiratory drive 13. Patients with the inability to maintain a patent airway or adequately clear secretions 14. Prisoners or other institutionalized individuals

Design outcomes

Primary

MeasureTime frameDescription
ICU length of stay of telemetry length of staywithin one week of hospital discharge (5-7 days)In patients admitted to the medical ICU, the primary endpoint is ICU length of stay. This will be the number of days a patient is admitted from day 1 of admission until the day of discharge. In patients admitted to medical telemetry unit, the outcome is telemetry length of stay. This will be the number of days a patient is admitted from day 1 of admission until the day of discharge.

Secondary

MeasureTime frameDescription
Time to normalization of pHat the time of hospital discharge (an average of 5-7 days)Time to normalization of pH (hours)
Normalization of pHat the time of hospital discharge (an average of 5-7 days)Return to normal range of pH as defined by the laboratory normal values (Binary measure)
Days on NIVwithin one week of hospital discharge (5-7 days)Days on noninvasive ventilation
Need for intubationwithin one week of hospital discharge (5-7 days)Need for intubation
Need for ICU staywithin one week of hospital discharge (5-7 days)Need for ICU stay (if disposition changed from telemetry unit)
Difference in PaCO2 value with NIVwithin 24-48 hours after noninvasive ventilationChange in paCO2 on ABG (paCO2 before and after NIV use, measured as a numerical value in mmHg)
Subgroup analysis (logistic regression or p-value) comparing outcome 2- difference in paCO2 reported as difference between groups (with p-value and/or standard deviation)through study completion, an average of 1 yearWe will perform subgroup analysis of each cause of hypercapnic respiratory failure (such as COPD, pulmonary edema, altered mental status, etc) for outcome 2- difference in PaCO2. We will use either logistic regression model or p-value to determine the difference for each subgroup. The results will be reported as difference between groups with statistical significance.
Subgroup analysis (logistic regression or p-value) comparing outcome 4- time to normalization of pH reported as difference between groups (with p-value and/or standard deviation)through study completion, an average of 1 yearWe will perform subgroup analysis of each cause of hypercapnic respiratory failure (such as COPD, pulmonary edema, altered mental status, etc) for outcome 4- time to normalization of pH. We will use either logistic regression model or p-value to determine the difference for each subgroup. The results will be reported as difference between groups with statistical significance.
Subgroup analysis (logistic regression or p-value) comparing outcome 5- days on NIV reported as difference between groups (with p-value and/or standard deviation)through study completion, an average of 1 yearWe will perform subgroup analysis of each cause of hypercapnic respiratory failure (such as COPD, pulmonary edema, altered mental status, etc) for outcome 5- days on NIV. We will use either logistic regression model or p-value to determine the difference for each subgroup. The results will be reported as difference between groups with statistical significance.
Subgroup analysis (logistic regression or p-value) comparing outcome 6- need for intubation reported as difference between groups (with p-value and/or standard deviation)through study completion, an average of 1 yearWe will perform subgroup analysis of each cause of hypercapnic respiratory failure (such as COPD, pulmonary edema, altered mental status, etc) for outcome 6- need for intubation. We will use either logistic regression model or p-value to determine the difference for each subgroup. The results will be reported as difference between groups with statistical significance.
Subgroup analysis (logistic regression or p-value) comparing outcome 7- need for ICU stay reported as difference between groups (with p-value and/or standard deviation)through study completion, an average of 1 yearWe will perform subgroup analysis of each cause of hypercapnic respiratory failure (such as COPD, pulmonary edema, altered mental status, etc) for outcome 7- need for ICU stay. We will use either logistic regression model or p-value to determine the difference for each subgroup. The results will be reported as difference between groups with statistical significance.
Subgroup analysis (logistic regression or p-value) comparing outcomes 1- ICU or telemetry length of stay based on the underlying cause of hypercapnic respiratory failurethrough study completion, an average of 1 yearWe will perform subgroup analysis of each cause of hypercapnic respiratory failure (such as COPD, pulmonary edema, altered mental status, etc) for these outcome- for 1. ICU or telemetry length of stay. We will use either logistic regression model or p-value to determine the difference for each subgroup. The results will be reported as difference between groups with statistical significance.

Countries

United States

Contacts

Primary ContactSara Velichkovikj
svelichkovik@northwell.edu(212)-434-4087

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026